IP Library Granted Patent US 9,125,921
Granted Patent B2
US 9,125,921 · App. 13/391,524 · Granted Sep 8, 2015

Picrorhiza extract for prevention, elimination and treatment of infection diseases

Inventors: Munisekhar Medasani (Hyderabad, IN); Satyasayee Babu Divi (Vishakapatnam, IN)
Assignee: MUNISEKHAR MEDASANI
A61K36/68
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,125,921
App. No.
13/391,524
Granted
Sep 8, 2015
Kind
B2
Abstract

An anti-viral composition comprising terpenes and fatty acids found in the Scophulariaceae family of plants is disclosed. It further comprises other lipophillic constituents and the aglycons of the glycosides occurring in said family of plants. Preferably, the composition is derived by extraction of the roots and rhizomes of mixtures of Picrorhiza kurrooa Royle, Picrorhiza scrophularflora Pennell and Neopicrorhiza scrophulańiflora . Solvents and solvent combinations are disclosed. The composition is effective against both DNA and RNA viruses and against fungal, bacterial, parasitic and protozoal infections and diseases and also as a hepatoprotective, anti-hyperlipidemic, anti-diabetic and kidney-protective agent. Anti bodies and vaccines for the cited diseases can be made by administration of the composition to animal or other subjects.

Claims (29)

1. A method of treatment comprising:

administering an adequate dose of a composition over an adequate period of time for the elimination, treatment or management of viral, bacterial, parasitic or protozoal infections, disorders or diseases either to a subject in need thereof, or during a biochemical, pharmaceutical, fermentation or biotech process in research or industry;

the composition comprising:

one or more terpenes, and

one or more fatty acids;

wherein:

the one or more terpenes and the one or more fatty acids include terpenes and fatty acids collected during a non-aqueous extraction using an ethanol hexane system of a plant matter from one or more plants selected from the group consisting of Neopicrorhiza scrophulariiflora and Picrorhiza scrophulariiflora Pennell;

the composition is substantially free of picrosides, other glycosides, and apocynin; and

the administration of an adequate dose of the composition over an adequate period of time is optionally followed by suitable maintenance doses of the composition over an adequate period of time.

2. The method of treatment as claimed in claim 1 , wherein the infections, disorders or diseases are caused by DNA viruses.

3. The method of treatment as claimed in claim 1 , wherein the infections, disorders or diseases are caused by RNA viruses.

4. The method of treatment as claimed in claim 1 , wherein the infections, disorders or diseases are selected from the group consisting of herpes, hepatitis virus, influenza, oropharyngeal candidiasis, zygomycosis, sporotrichosis, mycobacterium tuberculosis, streptococcus pneumoniae, enterohemorrahagic E. coli (EHEC), plasmodium parasite, HIV, and cancer causing retroviruses.

5. The method of treatment as claimed in claim 1 wherein the composition is:

administered in a form selected from the group consisting of powder, syrup, drink, tablet, caplet, softgel, capsule, nanogel, nano-particles, injections, parenteral, transdermal patches, absorbent gels, nasal sprays, vaginal gel, and adsorbed on an excipient; and

administered by a route selected from the group consisting of oral, intravenous, intramuscular, sub-cutaneous, peritoneal, rectal, nasal, trans-dermal, dermal, sublingual, and vaginal.

6. The method of treatment as claimed in claim 1 , wherein the composition further comprises one or more additional components collected during the extraction of the plant matter.

7. The method of treatment as claimed in claim 1 , wherein the dose of the composition contains the one or more terpenes and the one or more fatty acids in an amount in the range of from about 10 mg to about 1000 mg.

8. The method of treatment as claimed in claim 1 , wherein:

the one or more terpenes are selected from the group consisting of steroidal triterpenes, steroidal triterpene esters, steroidal triterpene fatty acids, and steroidal triterpenes fatty acid esters; and

the one or more fatty acids are selected from the group consisting of long chain fatty acids.

9. The method of treatment as claimed in claim 1 , wherein the subject in need thereof is an animal.

10. The method of treatment as claimed in claim 1 , wherein the adequate dose of the composition is administered during a biotech process.

11. The method of treatment as claimed in claim 10 , wherein the adequate dose of the composition is administered to microorganisms.

12. The method of treatment as claimed in claim 1 , wherein the adequate dose of the composition is administered against bacterial infections in biochemical, pharmaceutical, or biotech processes in research or industry.

13. The method of treatment as claimed in claim 1 , wherein the hexane solvent is n-hexane.

14. The method of treatment as claimed in claim 1 , wherein the hexane solvent is c-hexane.

15. The method of treatment as claimed in claim 1 , wherein the adequate dose of the composition is in the form of a food/dietary supplement, a medicine, or an alternative medicine with or without added adjuvants.

16. The method of treatment as claimed in claim 1 , wherein the subject in need thereof is a human.

17. The method of treatment as claimed in claim 1 , wherein the plant matter is from Neopicrorhiza scrophulariiflora.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2024
From: MEDASANI, MUNISEKHAR
To: ASTREL GENOME LIMITED
Reel/Frame 069477/0315 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2012
From: DIVI, SATYASAYEE BABU
To: MUNISEKHAR MEDASANI
Reel/Frame 028345/0036 →
Priority Claims (1)
IN 2150/CHE/2009 · Sep 4, 2009 · national
Continuity (1)
Related Publication 20120148569A1 · Jun 14, 2012